Observing the use of Oxycodone for cancer pain management
The Efficacy and Safety of Oxycodone Hydrochloride Sustained-release Tablets in the Treatment of Moderate to Severe Cancer Pain：A Multicenter Real World Study
This study is testing how well Oxycodone can help people with moderate to severe cancer pain manage their discomfort in everyday settings.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 916 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Henan Cancer Hospital Government |
| Locations | 1 site (Zhengzhou, Henan) |
| Trial ID | NCT05962294 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the efficacy and safety of Oxycodone Hydrochloride Sustained-release Tablets in patients experiencing moderate to severe cancer pain in real-world clinical settings. Participants will undergo a 14-day treatment cycle where their daily medication doses will be adjusted based on their pain levels and other relevant health metrics. Data collected will include pain scores, medication dosages, and vital signs to assess the overall effectiveness and safety of the treatment. The study does not include a control group, focusing instead on real-world outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with moderate to severe cancer pain who require Oxycodone treatment.
Not a fit: Patients with severe mental illness who cannot cooperate with follow-up will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effective management of cancer pain using Oxycodone, potentially improving patient quality of life.
How similar studies have performed: While there have been studies on opioid use for cancer pain, this specific real-world observational approach is less common and may provide novel insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Voluntarily sign an informed consent form; 2. Age ≥ 18 years old; 3. Patients with moderate to severe (NRS ≥ 4 points) cancer pain; 4. Patients with oral equivalent Oxycodone Hydrochloride Sustained-release Tablets ≥ 80mg/d. Exclusion Criteria: 1. Patients with severe mental illness who cannot cooperate with follow-up
Where this trial is running
Zhengzhou, Henan
- Henan Cancer Hospital — Zhengzhou, Henan, China (Recruiting)
Study contacts
- Study coordinator: Suxia Luo, Doctor
- Email: luosxrm@163.com
- Phone: +86 18638553211
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.